Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Abbisko (和誉) IPO: Fairly Valued for the Early Stage of Clinical Trials

Abbisko (和誉) Pre-IPO: Thoughts on Valuation

Abbisko (和誉) Pre-IPO: Strong Team but FGFR Inhibitors Not Convincing Yet

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Abbisko raised HKD 1,605 million (USD 206m) from its global offering and will list on the Hong Kong Stock Exchange on Wednesday, October 13th.
In our previous note, we discussed that the company's product pipeline has a strong focus on selective FGFR small molecules for oncology therapy. Its core products ABSK011 is an FGFR4 inhibitor and ABSK091 is a pan-FGFR inhibitor, which was in-licensed from AstraZeneca with global rights. We think its products have yet to show convincing clinical numbers despite strong prospects from pre-clinical readings. We think the company's management team is experienced with a proven track record of product development and commercialization. The investor line-up is strong. We also provide forecast and valuation for the two core products, ABSK011 and ABSK091. 
In this note, we look at the updates since our last note. We re-iterate our view that the company is fairly valued for the early stage of R&amp;D despite interesting comprehensive coverage on the FGFR targets.

Abbisko raised HKD 1,605 million (USD 206m) from its global offering and will list on the Hong Kong Stock Exchange on Wednesday, October 13th.
In our previous note, we discussed that the company's product pipeline has a strong focus on selective FGFR small molecules for oncology therapy. Its core products ABSK011 is an FGFR4 inhibitor and ABSK091 is a pan-FGFR inhibitor, which was in-licensed from AstraZeneca with global rights. We think its products have yet to show convincing clinical numbers despite strong prospects from pre-clinical readings. We think the company's management team is experienced with a proven track record of product development and commercialization. The investor line-up is strong. We also provide forecast and valuation for the two core products, ABSK011 and ABSK091. 
In this note, we look at the updates since our last note. We re-iterate our view that the company is fairly valued for the early stage of R&amp;D despite interesting comprehensive coverage on the FGFR targets.

Abbisko (和誉) IPO Trading: Poor Demand for the Early Stage R&D

Abbisko Cayman

Abbisko (和誉) IPO Trading: Poor Demand for the Early Stage R&D